Understanding the pathophysiology of diabetic neuropathy
Neuropathic pain affects nearly 50% of people with diabetes, yet our understanding of the pathophysiology remains incomplete. MD Biosciences aims to provide efficacy studies with greater insight into the clinical condition by going beyond the standard assessments. Adding clinically relevant measures such as electrophysiology and IENF staining provide insight into the pathophysiology of these peripheral neuropathies.
Diabetic Neuropathy Models
-
Diabetes Neurodegeneration In Vitro Screening Assay
A hallmark of degeneration is the blebbing of neurites, which is when neurites begin disassembly and degeneration. The neurodegeneration index (NI) compares the relative area of neurites and the number of neurites.
The Diabetes Neurodegeneration in vitro screening assay utilizes primary neurons from immature mice or rats. Following the conditioning phase with high concentrations of glucose, cultures are treated with compounds and evaluated for their neurodegeneration index.
The assays are ideal for screening compounds prior to efficacy in in vivo studies.
-
STZ-induced Diabetic Neuropathy Model
STZ is used to induce type I diabetes and diabetes-related complications, including diabetic peripheral neuropathy. There are multiple theories on the mechanism that involves peripheral neuropathy following STZ. Some of the mechanisms suggested are related to the hyperglycemic state of the rats suggesting that following the hyperglycemia, nerve endings are damaged either through an inflammatory process or interfering with blood supply. However, vast studies are also suggesting a mechanism of neuronal damage that occurs following STZ but it is unrelated to the hyperglycemic state of the animals.
These studies suggest direct damage to the nerves. For example, reactive oxygen species (ROS) mediate elevation of TRPV1 in neurons and the DRG is exposed to STZ in vitro. Therefore, the STZ model involves direct changes in the nerves that are not related to the inflammatory process.
Assessments
- Blood glucose measurements, tactile/mechanical allodynia
- Histology and biomarker analysis (protein or mRNA) of sciatic nerve or paw skin)
-
High Fat Diet (HFD) Induced Diabetes and Peripheral Neuropathy
The high fat diet induced diabetic model is used to study peripheral neuropathy from diabetes types II. Food intake and body weight are measured along with blood glucose levels to determine the onset of type II diabetes.
Measures:
- Body weight
- Food intake
- Glucose tolerance (GTT)
- Blood glucose level (BGL)
- Von Frey
- Electrophysiology: nSEP-induced withdrawal reflex
Assessments
MD Biosciences incorporates a range of in vivo measures and endpoint assessments that provide a robust data package that enable researchers to make critical decisions.
Behavior
Pain behavior tests assess the response to various pain stimuli.
Biomarkers
Evaluate pro-inflammatory and anti-inflammatory biomarkers in samples.
Histology
IHC and histological staining to evaluate neuroinflammation and pain-related markers.
Electrophysiology
Evaluate spontaneous nerve firing using in vivo electrophysiology.
Scientific Data
Evaluating cytokine levels in plasma and CSF supports the understanding of mode of action and the drug effect. STZ alters plasma cytokines in male rats. In STZ animals there are significant differences in these three markers compared to naïve animals. TNF-a and RANTES levels increased while IL-10 levels decreased.
Review the complete dataset.
Diabetic Neuropathic Pain Datasheet
Complete the short form for instant access to the complete data set.